Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)

Catherine R. Hanna* (Corresponding Author), Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Leslie Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Daniel R. Gaya, Caroline A. Kelly, Liz-Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt, Fiona Thomson, Richard A. Adams, Campbell S. D. Roxburgh

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Advances in multi-modality treatment of locally advanced rectal cancer (LARC) have resulted in low local recurrence rates, but around 30% of patients will still die from distant metastatic disease. In parallel, there is increasing recognition that with radiotherapy and systemic treatment, some patients achieve a complete response and may avoid surgical resection, including in many cases, the need for a permanent stoma. Extended neoadjuvant regimes have emerged to address these concerns. The inclusion of immunotherapy in the neoadjuvant setting has the potential to further enhance this strategy by priming the local immune microenvironment and engaging the systemic immune response.
Original languageEnglish
Article number163
Number of pages9
JournalRadiation Oncology
Volume16
Issue number1
DOIs
Publication statusPublished - 26 Aug 2021

Keywords

  • Rectal
  • neoplasm
  • chemotherapy
  • radiotherapy
  • immune-oncology
  • immunotherapy
  • clinical trial

Fingerprint

Dive into the research topics of 'Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)'. Together they form a unique fingerprint.

Cite this